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8th-9th November, 2018 
LYSOSOMAL STORAGE DISORDERS (LSDS)
 Genetic
 Rare
 Autosomal recessive (majority)
 Portugal - 1/4000
 Almost 70!
9th November, 2018 
LYSOSOMAL STORAGE DISORDERS (LSDS)
 Chronic
 Progressive
 Large spectrum of severity 
& symptoms 
CNS pathology is a common hallmark of 
LSDs
LSDs are the commonest cause of 
paediatric neurodegenerative disease
9th November, 2018 
LYSOSOMAL STORAGE DISORDERS (LSDS)
 Chronic
 Progressive
 Large spectrum of severity 
& symptoms 
(from in utero/paediatric
to late adult onset forms)
 Pathophysiology
still unknown!
9th November, 2018 
LYSOSOMAL STORAGE DISORDERS (LSDS)
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LYSOSOMAL STORAGE DISORDERS (LSDS)
9th November, 2018 
 Progressive accumulation
LYSOSOMAL STORAGE DISORDERS (LSDS)
9th November, 2018 
 Progressive accumulation
LYSOSOMAL STORAGE DISORDERS (LSDS)
?
9th November, 2018 
 1969
 Elizabeth Neufeld
THE ENZYME AS A DRUG?
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9th November, 2018 
PROOF OF PRINCIPLE…
 Gaucher Disease (GD)
 Deficient enzyme: -glucocerebrosidase
 Gene: GBA (1q21)
 Most frequent LSD
Original illustration by Marcos Bernardino for  
Cristiana Petriz´s “Gigi e a Doença de Gaucher”, 2010
9th November, 2018 
PROOF OF PRINCIPLE…
 Gaucher Disease (GD)
 Deficient enzyme: -glucocerebrosidase
 Gene: GBA (1q21)
 Missing enzyme 
 isolated from human 
placentae
o IV injection into patients
o extraordinary results 
in blood tests!
Original illustration by Marcos Bernardino for  
Cristiana Petriz´s “Gigi e a Doença de Gaucher”, 2010
9th November, 2018 
PROOF OF PRINCIPLE…
 Gaucher Disease (GD)
 Deficient enzyme: -glucocerebrosidase
 Gene: GBA (1q21)
 Intravenous injections of the 
recombinant enzyme
 Excellent results in systemic 
disease
Original illustration by Marcos Bernardino for  
Cristiana Petriz´s “Gigi e a Doença de Gaucher”, 2010
THE ENZYME AS A DRUG?
Pathology Available ERT
Gaucher Cerezyme® VPRIV®                                     Elelyso® 
(Imiglucerase; Genzyme) (Velaglucerase alfa; Shire) (Taliglucerase alfa; Pfizer)
Fabry Replagal® Fabrazyme®



















 Ineffective for the CNS manifestations
…antibodies?
…secondary effects?
THE ENZYME AS A DRUG?

































most has no treatment! 
9th November, 2018 
STILL SO MUCH TO DO…
9th November, 2018 





possibilities are limitless”… 
9th November, 2018 
enzyme replacement therapies
more effective
able to cross the BBB
“WITH RESEARCH, POSSIBILITIES ARE LIMITLESS”…
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“WITH RESEARCH, POSSIBILITIES ARE LIMITLESS”…
 Final goal: brain
How?
intrathecal injection
(into the spinal canal/subarachnoid space so that it 
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 Final goal: brain
How?
intracerebroventricular injections
“WITH RESEARCH, POSSIBILITIES ARE LIMITLESS”…
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“WITH RESEARCH, POSSIBILITIES ARE LIMITLESS”…
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“WITH RESEARCH, POSSIBILITIES ARE LIMITLESS”…








9th November, 2018 
 ‘Broader’ approaches
i.e. 1 therapy  1 disease
(or  even more!)
 ‘Personalized’ approaches
i.e. 1 therapy for each mutation/
type of mutation
“WITH RESEARCH, POSSIBILITIES ARE LIMITLESS”…




able to cross the BBB
“WITH RESEARCH, POSSIBILITIES ARE LIMITLESS”…
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 ‘Broader’ approaches
“WITH RESEARCH, POSSIBILITIES ARE LIMITLESS”…
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 ‘Broader’ approaches
Genetic substrate reduction
“WITH RESEARCH, POSSIBILITIES ARE LIMITLESS”…
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“WITH RESEARCH, POSSIBILITIES ARE LIMITLESS”…
 ‘Personalized’ approaches
Final goal: 
correction/amellioration of 1 mutation               in particular




promote their transport into the lysosome
9th November, 2018 











9th November, 2018 


“WITH RESEARCH, POSSIBILITIES ARE LIMITLESS”…
 ‘Personalized’ approaches
Final goal: 
correction/amellioration of 1 mutation               in particular
type of mutations 
How?
 Correction of splicing mutations
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Our work at PT National Institute of Health…
 ‘Broader’ approaches
 gSRT for MPS
 ‘Personalized’ approaches




‘Easy’ to test at a cellular level – 1st stage
9th November, 2018 
THE FUTURE(S)…
gSRT +          enzyme replacement therapy
9th November, 2018 
gene therapy
THE FUTURE(S)…
9th November, 2018 
Personalized therapies
THE FUTURE(S)…
9th November, 2018 
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